Stewart Abbot
Company: Turnstone Therapeutics
Job title: Chief Scientific Officer
Seminars:
Unveiling the Impact of Tumor-Infiltrating Lymphocytes (TILs) on Solid Tumors & the TCR Landscape 5:40 pm
• Exploring the potential of TILs as a groundbreaking avenue for cancer treatment by leveraging the body’s immune system to combat solid tumors • Understanding the pivotal role of TILs as prognostic indicators and their ability to infiltrate and target solid tumor microenvironments for therapeutic interventions • Delving into the diverse and specialized T cell…Read more
day: Conference Day One
Panel: Unveiling Distinctions: Evaluating TCR-T Cell Therapies, CAR-T, TCR Bispecifics, & Antibody Mimetics for Tailored Therapeutic Advancements 4:05 pm
• Quantifying Effectiveness: Comparing the relative affinities, potencies, and safety profiles of T-cell therapies, CAR-T, TCR bispecifics and antibody mimetics to discern their unique therapeutic characteristics • Strategic Suitability: Assessing the optimal indications and patient populations where each TCR modality excels • Beyond the Horizon: Exploring potential future modalities in the TCR therapy landscape, envisioning…Read more
day: Conference Day One
Unveiling the Impact of Tumor-Infiltrating Lymphocytes (TILs) on Solid Tumors & the TCR Landscape 5:00 pm
Exploring the potential of TILs as a groundbreaking avenue for cancer treatment by leveraging the body’s immune system to combat solid tumors Understanding the pivotal role of TILs as prognostic indicators and their ability to infiltrate and target solid tumor microenvironments for therapeutic interventions Delving into the diverse and specialized T-cell receptor (TCR) repertoires present…Read more
day: DAY ONE TRACK 4 A
Panel: Unveiling Distinctions: Evaluating TCR-T Cell Therapies, CAR-T, TCR Bispecifics, & Antibody Mimetics for Tailored Therapeutic Advancements 3:00 pm
Quantifying Effectiveness: Comparing the relative affinities, potencies, and safety profiles of T-cell therapies, CAR-T, TCR bispecifics and antibody mimetics to discern their unique therapeutic characteristics Strategic Suitability: Assessing the optimal indications and patient populations where each TCR modality excels Beyond the Horizon: Exploring potential future modalities in the TCR therapy landscape, envisioning the untapped possibilities…Read more
day: DAY ONE TRACK 3 A